Trade Boliden AB - BOLs
Boliden is a Sweden-based company involved in exploring, extracting and processing base and precious metals.The high-tech metal company takes its origins in 1924 when gold fever broke out close to the Swedish town of Skelleftea. That first ore deposit laid the foundations for today’s Boliden Group. The company divides its operations into the Business Area Smelters and Business Area Mines segments. Boliden’s principal products are zinc, copper, lead, nickel, gold, silver, sulphuric acid, concentrate, and by-products. The group’s operation network stretches across Sweden, Finland, Norway, and Ireland. Their key markets include Germany, Scandinavia and the UK. Boliden trades on the NASDAQ Stockholm exchange under the ticker BOL. Explore the latest Boliden share price info and tap into Sweden’s Large Cap segment with Capital.com.Latest shares articles

BNP Paribas stock forecast: Q2 earnings beat estimates
BNP Paribas is a French banking group whose recent developments include a Swift ledger transaction with HSBC for Siemens and continued focus on eurozone interest rates. Explore third-party BNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
8 hours ago

Boeing stock forecast: FAA investigates Miami freighter crash
Boeing is a US aerospace manufacturer whose shares remain in focus after a 767-300 freighter crash in Miami prompted an FAA investigation. Explore third-party BA price targets and technical analysis. Past performance is not a reliable indicator of future results.
9 hours ago

CaixaBank stock forecast: BPI exits Angola market
CaixaBank is a Spanish bank whose Portuguese unit, Banco BPI, agreed to sell its 33.35% stake in Banco de Fomento de Angola for €388.5m. Explore third-party CABK price targets and technical analysis. Past performance is not a reliable indicator of future results.
10 hours ago

Valneva stock forecast: EMA validates Lyme vaccine application
Valneva is a French vaccine company listed on Euronext Paris. In August, the EMA validated the marketing-authorisation application for its Lyme disease vaccine candidate with Pfizer. Explore third-party VLA price targets. Past performance is not a reliable indicator of future results.
13 hours ago
Related News
Stockholm Stock Exchange